

Kristin A Altwegg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4042278/publications.pdf>

Version: 2024-02-01

9
papers

120
citations

1478505

6
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

107
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC. <i>Cancers</i> , 2022, 14, 930.	3.7	5
2	SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance. <i>Breast Cancer Research</i> , 2022, 24, 26.	5.0	12
3	Interaction of transcription factor AP2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling. <i>Molecular Oncology</i> , 2021, 15, 1146-1161.	4.6	15
4	LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer. <i>Cell Death Discovery</i> , 2021, 7, 216.	4.7	16
5	Role of estrogen receptor coregulators in endocrine resistant breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, 385-400.	0.8	6
6	Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab099.	0.7	5
7	LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. <i>Communications Biology</i> , 2021, 4, 1235.	4.4	11
8	PELP1 signaling contributes to medulloblastoma progression by regulating the NF- κ B pathway. <i>Molecular Carcinogenesis</i> , 2020, 59, 281-292.	2.7	9
9	EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1341-1354.	4.1	41